PMID- 10335479
OWN - NLM
STAT- MEDLINE
DCOM- 19990712
LR  - 20191103
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 22
IP  - 3
DP  - 1999 May
TI  - Tumor angiogenesis and endothelial cell modulatory factors.
PG  - 186-211
AB  - Angiogenesis is the ability of preexisting vasculature to send out capillary
      sprouts leading to the formation of new vasculature. It is now a well-accepted
      idea that progression of solid tumors is intrinsically dependent on angiogenesis 
      for growth of the primary tumor and metastatic lesions. Investigations into tumor
      angiogenesis have focused on inhibition of tumor neovasculature as yet another
      possible mechanism for impairing tumor progression. Numerous studies have
      characterized cellular and molecular factors important to vascular formation and 
      development and have led to the identification and understanding of requisite
      interactions between endothelium, angiogenic cytokines, and the supporting
      matrix. These studies have also led to the identification of cytokines involved
      in the proteolytic disruption of the basement membrane, the migration of
      endothelial cells, and the proliferation and formation of neoendothelium into
      functional vasculature. As therapies based on antiangiogenic strategies continue 
      to evolve and clinical trials are conducted, these agents may become an important
      part of the arsenal against tumor proliferation, especially given their favorable
      toxicity profile. This review discusses the angiogenic cytokines which have been 
      most intensely studied and the receptors they act upon. Additionally, we discuss 
      select proteases and their importance in the development of neovasculature. A
      better understanding of these components will help in the development of novel
      therapeutic strategies.
FAU - Desai, S B
AU  - Desai SB
AD  - Surgical Metabolism Section, National Cancer Institute, National Institutes of
      Health, Bethesda, MD 20892-1502, USA.
FAU - Libutti, S K
AU  - Libutti SK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Cytokines)
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Growth Inhibitors)
SB  - IM
CIN - J Immunother. 1999 May;22(3):185. PMID: 10335478
MH  - Antineoplastic Agents
MH  - Cell Adhesion Molecules
MH  - Cytokines
MH  - Endothelial Growth Factors
MH  - *Endothelium, Vascular
MH  - Extracellular Matrix
MH  - Growth Inhibitors
MH  - Humans
MH  - Neoplasms/*blood supply/genetics/therapy
MH  - *Neovascularization, Pathologic/prevention & control
MH  - Oncogenes
RF  - 346
EDAT- 1999/05/21 00:00
MHDA- 1999/05/21 00:01
CRDT- 1999/05/21 00:00
PHST- 1999/05/21 00:00 [pubmed]
PHST- 1999/05/21 00:01 [medline]
PHST- 1999/05/21 00:00 [entrez]
AID - 10.1097/00002371-199905000-00002 [doi]
PST - ppublish
SO  - J Immunother. 1999 May;22(3):186-211. doi: 10.1097/00002371-199905000-00002.